Oral anticoagulation therapy in atrial fibrillation patients at high risk of bleeding: Clinical characteristics and treatment strategies based on data from the Polish …
M Maciorowska, B Uziębło-Życzkowska… - Polish Heart …, 2024 - journals.viamedica.pl
Background: Despite its benefits, oral anticoagulant (OAC) therapy in patients with atrial
fibrillation (AF) is associated with hemorrhagic complication s. Aims: We aimed to evaluate …
fibrillation (AF) is associated with hemorrhagic complication s. Aims: We aimed to evaluate …
Low bleeding acceptance is associated with increased death risk in patients with atrial fibrillation on oral anticoagulation
G Rusin, M Konieczyńska, J Natorska… - Journal of Thrombosis …, 2024 - Springer
Bleeding is the most feared complication of anticoagulation. We sought to investigate
whether the bleeding risk acceptance has a prognostic value during long-term follow-up in …
whether the bleeding risk acceptance has a prognostic value during long-term follow-up in …
The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society
E Kazimierczyk, M Dąbrowska… - Polish Heart …, 2024 - journals.viamedica.pl
Andexanet alfa (AA) is a recombinant inactive analog of human activated factor X (FXa),
effectively reversing the effects of its inhibitors—rivaroxaban and apixaban, which are …
effectively reversing the effects of its inhibitors—rivaroxaban and apixaban, which are …
The DOAC score is associated with elevated growth differentiation factor 15 and 3-nitrotyrosine in atrial fibrillation: prediction of bleeding at one-year follow-up
P Mołek-Dziadosz, J Natorska… - Polish Heart …, 2024 - journals.viamedica.pl
Atrial fibrillation (AF) patients on oral anticoagulation are at greater risk of major bleeding.
Existing clinical decision-making aids for evaluating the risk of bleeding in AF patients were …
Existing clinical decision-making aids for evaluating the risk of bleeding in AF patients were …
Stanowisko ekspertów Polskiego Towarzystwa Kardiologicznego dotyczące stosowania andeksanetu alfa w warunkach polskich—interdyscyplinarny protokół
E Kazimierczyk, M Dąbrowska… - Polish Heart …, 2023 - journals.viamedica.pl
Andeksanet alfa (AA) jest rekombinowanym, nieaktywnym analogiem ludzkiego czynnika Xa
(FXa), skutecznie odwracającym działanie jego inhibitorów—dostępnych w Polsce …
(FXa), skutecznie odwracającym działanie jego inhibitorów—dostępnych w Polsce …